[1] KINCH MS,KRAFT Z,SCHWARTZ T.Monoclonal antibodies:trends in therapeutic success and commercial focus[J].Drug Discov Today,2023,28(1):103415
[2] CRESCIOLI S,KAPLON H,CHENOWETH A,et al.Antibodies to watch in 2024[J].Mabs,2024,16(1):2297450
[3] BAI S,JORGA K,XIN Y,et al.A guide to rational dosing of monoclonal antibodies[J].Clin Pharmacokinet,2012,51(2):119
[4] HENDRIKX JJMA,HAANEN JBAG,VOEST EE,et al.Fixed dosing of monoclonal antibodies in oncology[J].Oncologist,2017,22(10):1212
[5] GILL KL,MACHAVARAM KK,ROSE RH,et al.Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics[J].Clin Pharmacokinet,2016,55(7):789
[6] BASELGA J,CARBONELL X,CASTANEDA-SOTO NJ,et al.Phase Ⅱ study of efficacy,safety,and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule[J].J Clin Oncol,2005,23(10):2162
[7] GADSBY J,HALL K,SHAH F,et al.Infliximab:a single-centre,prospective,observational evaluation of TDM data in patients with IBD[J].Eur J Hosp Pharm,2023,31(1):16
[8] PAPAMICHAEL K,VOGELZANG EH,LAMBERT J,et al.Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases[J].Expert Rev Clin Immunol,2019,15(8):837
[9] OKINES AF,CUNINGHAM D.Trastuzumab in gastric cancer[J].Eur J Cancer,2010,46(11):1949
[10] HORTOBAGYI GN.Trastuzumab in the treatment of breast cancer[J].New England J Med,2005,353(16):1734
[11] GEMMETE JJ,MUKHERJI SK.Trastuzumab(herceptin)[J].Am J Neuroradiol,2011,32(8):1373
[12] GHOSH R,NARASANNA A,WANG SE,et al.Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers[J].Cancer Res,2011,71(5):1871
[13] MAADI H,NAMI B,TONG J,et al.The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2[J].BMC Cancer,2018,18(1):238
[14] SCHEUER W,FRIESS T,BURTSCHER H,et al.Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models[J].Cancer Res,2009,69(24):9330
[15] BASELGA J,SWAIN SM.Novel anticancer targets:revisiting ERBB2 and discovering ERBB3[J].Nat Rev Cancer,2009,9(7):463
[16] OWONIKOKO TK,PARK K,GOVINDAN R,et al.Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer:CheckMate451[J].J Clin Oncol,2021,39(12):1349
[17] BAAS P,SCHERPEREEL A,NOWAK AK,et al.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma(CheckMate743):a multicentre,randomised,open-label,phase 3 trial[J].Lancet,2021,397(10272):375
[18] TODOROKI K,MIZUNO H,SUGIYAMA E,et al.Bioanalytical methods for therapeutic monoclonal antibodies and antibody-drug conjugates:a review of recent advances and future perspectives[J].J Pharm Biomed Anal,2020,179:112991
[19] ZHANG B,WHITEAKER JR,HOOFNAGLE AN,et al.Clinical potential of mass spectrometry-based proteogenomics[J].Nat Rev Clin Oncol,2019,16(4):256
[20] WILFFERT D,BISCHOFF R,VAN DE MERBEL NC.Antibody-free workflows for protein quantification by LC-MS/MS[J].Bioanalysis,2015,7(6):763
[21] GAHOUAL R,HEIDENREICH AK,SOMSEN GW,et al.Detailed characterization of monoclonal antibody receptor interaction using affinity liquid chromatography hyphenated to native mass spectrometry[J].Anal Chem,2017,89(10):5404
[22] ZHAO WW,LIU FF,SHI QH,et al.Octapeptide-based affinity chromatography of human immunoglobulin G:comparisons of three different ligands[J].J Chromatogr A,2014,1359:100
[23] DOS SANTOS R,ROSA SA,AIRES-BARROS MR,et al.Phenylboronic acid as a multi-modal ligand for the capture of monoclonal antibodies:development and optimization of a washing step[J].J Chromatogr A,2014,1355:115
[24] ALVES NJ,STIMPLE SD,HANDLOGTEN MW,et al.Small-molecule-based affinity chromatography method for antibody purification via nucleotide binding site targeting[J].Anal Chem,2012,84(18):7721
[25] DUTTA AK,TRAN T,NAPADENSKY B,et al.Purification of monoclonal antibodies from clarified cell culture fluid using protein A capture continuous countercurrent tangential chromatography[J].J Biotechnol,2015,213:54
[26] ZHAO WW,SHI QH,SUN Y.Dual-ligand affinity systems with octapeptide ligands for affinity chromatography of hIgG and monoclonal antibody[J].J Chromatogr A,2014,1369:64
[27] NAIK AD,RAINA M,LALI AM.AbSep-an amino acid based pseudobioaffinity adsorbent for the purification of immunoglobulin G[J].J Chromatogr A,2011,1218(13):1756
[28] Bioanalytical Method Validation Guidance for Industry[S/OL].[2024-12-08].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf
[29] KLEINE-BRUEGGENEY M,MUSSHOFF F,STUBER F,et al.Pharmacogenetics in palliative care[J].Forensic Sci Int,2010,203(1-3):63
[30] CAMPERI SA,IANNUCCI NB,ALBANESI GJ,et al.Monoclonal antibody purification by affinity chromatography with ligands derived from the screening of peptide combinatory libraries[J].Biotechnol Lett,2003,25(18):1545
[31] WEI Y,XU J,ZHANG L,et al.Development of novel small peptide ligands for antibody purification[J].RSC Adv,2015,5:67093
[32] MARINO M,RUVO M,DE FALCO S,et al.Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide[J].Nat Biotechnol,2000,18(7):735
[33] SUGITA T,KATAYAMA M,OKOCHI M,et al.Screening of peptide ligands that bind to the Fc region of IgG using peptide array and its application to affinity purification of antibody[J].Biochem Eng J,2013,79:33
[34] KRULJEC N,MOLEK P,HODNIK V,et al.Development and characterization of peptide ligands of immunoglobulin G Fc region[J].Bioconjug Chem,2018,29(8):2763
[35] EHRLICH GK,BAILON P.Identification of model peptides as affinity ligands for the purification of humanized monoclonal antibodies by means of phage display[J].J Biochem Biophys Methods,2001,49(1-3):443
[36] WANG W,HAO D,GE J,et al.A minimalist peptide ligand for IgG by minimizing the binding domain of protein A[J].Biochem Eng J,2019,151:107327
[37] LEI Y,SHEN Y,ZUO C,et al.Emerging affinity ligands and support materials for the enrichment of monoclonal antibodies[J].TrAC Trend Anal Chem,2022,157:116744
[38] LIU L,CHEN X,SUN BO.Construction of a recyclable DNAzyme motor for MUC1-specific glycoform in situ quantification[J].Anal Chem,2022,94(40):13745
[39] LIU L,KUANG Y,WANG Z,et al.A photocleavable peptide-tagged mass probe for chemical mapping of epidermal growth factor receptor 2(HER2)in human cancer cells[J].Chem Sci,2020,11,11298
[40] SUN B,LIU J,CAI P,et al.Aptamer-based sample purification for mass spectrometric quantification of trastuzumab in human serum[J].Talanta,2023,257:124349
[41] LI N,PALANDRA J,NEMIROVSKIY OV,et al.LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species[J].Anal Chem,2009,81(6):2251
[42] ZHANG Y,LI N,BROWN PW,et al.Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples[J].Rapid Commun Mass Spectrom,2011,25(12):1715
